Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer

doi:10.4251/wjgo.v17.i5.105872

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1481)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-5) series.

Item

Count

PDF

HTML

701

Figures (1-7)

183

Tables (1-5)

185

Sum=1137

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

242

Sum=279

May 15, 2025 (publication date) through Aug 13, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. May 15, 2025; 17(5): 105872
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105872

Full Size Figure Download Figure

Figure 1 Patient selection diagram. HCC: Hepatocellular carcinoma; ECGO: Eastern Cooperative Oncology Group; AASLD: American Association for the Study of Liver Diseases; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization; TIPM: Target Immunotherapy Predictive Model.

Citation: Tu HB, Feng SY, Chen LH, Huang YJ, Zhang JZ, Peng SY, Lin DL, Ye XJ. Integrating ultrasound and serum indicators for evaluating outcomes of targeted immunotherapy in advanced liver cancer. World J Gastrointest Oncol 2025; 17(5): 105872
URL: https://www.wjgnet.com/1948-5204/full/v17/i5/105872.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.105872